無料プレビュー

Roivant Sciences Ltd. (ROIV) · NASDAQ Global Market

プロフィール

Roivant Sciences Ltd. is a biopharmaceutical company that develops and commercializes medicines through subsidiary companies called Vants, each focused on specific product candidates. The company's pipeline includes brepocitinib (small molecule JAK1/TYK2 inhibitor for autoimmune diseases), IMVT-1402 (monoclonal antibody targeting FcRn for IgG-mediated autoimmune indications), and mosliciguat (inhaled sGC activator for pulmonary hypertension). Roivant operates through subsidiaries including Priovant, Immunovant, Pulmovant and Genevant, with geographic focus on the U.S., E.U., Canada and other r

主要指標

株価: $34.21 (-1.55%)
時価総額: 247億ドル
PER（今期予想）: -24.8
PBR: 5.8
配当利回り: —
52週レンジ: $15.90 – $42.50
業種: Healthcare / Biotechnology
上場: NASDAQ Global Market
構成銘柄: —

比較会社: VRTX Vertex Pharmaceuticals Incorporated、MRNA Moderna, Inc.、REGN Regeneron Pharmaceuticals, Inc.、ARGX argenx SE、SGEN Seagen Inc.、RVMD Revolution Medicines, Inc.、ONC BeOne Medicines AG、BIIB Biogen Inc.

長期トレンド・直近動向・強気／弱気シナリオ・業績10年・バリュエーション・テクニカル・株主・役員・深掘り分析は会員向けです。

7日間無料で全文を読むログイン

次回決算: 2026-11-09 · 更新: 2026-10-09